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Abstract
Genome-wide association (GWA) studies have identified a number of loci underlying variation in human serum uric acid
(SUA) levels with the SLC2A9 gene having the largest effect identified so far. Gene-gene interactions (epistasis) are largely
unexplored in these GWA studies. We performed a full pair-wise genome scan in the Italian MICROS population (n = 1201) to
characterise epistasis signals in SUA levels. In the resultant epistasis profile, no SNP pairs reached the Bonferroni adjusted
threshold for the pair-wise genome-wide significance. However, SLC2A9 was found interacting with multiple loci across the
genome, with NFIA - SLC2A9 and SLC2A9 - ESRRAP2 being significant based on a threshold derived for interactions between
GWA significant SNPs and the genome and jointly explaining 8.0% of the phenotypic variance in SUA levels (3.4% by
interaction components). Epistasis signal replication in a CROATIAN population (n = 1772) was limited at the SNP level but
improved dramatically at the gene ontology level. In addition, gene ontology terms enriched by the epistasis signals in each
population support links between SUA levels and neurological disorders. We conclude that GWA epistasis analysis is useful
despite relatively low power in small isolated populations.
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Introduction
Serum uric acid is the final oxidation product of purine
metabolism in humans. High serum uric acid (SUA) levels can lead
to gout and is associated with cardiovascular diseases and diabetes
[1], whereas low SUA levels may be associated with multiple
sclerosis [2,3]. High SUA levels are increasingly prevalent
(reaching 15–20%) in many human populations and caused
mainly by impaired renal excretion of urate [4]. Elevated urate is
associated with insulin resistance [5] and neurological disorders
such as Parkinson’s disease [6,7]. About 70% of SUA is excreted
via the kidneys and the remainder is eliminated into the biliary
tract and intestine, part of which is subsequently converted by
colonic bacterial uricase to allantoin [4].
SUA level is a complex trait that is affected by environmental
(e.g. diet and excessive body weight) and genetic factors with
heritability estimates of 60–87% [8,9]. Genome-wide association
(GWA) studies so far have identified nine loci underlying SUA
levels. Seven of these loci are membrane transporters suggesting
that the genetic variation in urate transport proteins plays an
important role [10,11,12]. The variants identified within the
SLC2A9 gene are the most significant genetic risk factors
associating with low fractional excretion of SUA and explain
5.3% of the SUA level variance in women and 1.7% of the SUA
level variance in men in the VIS population [12]. However,
because each of the eight remaining loci carries moderate
marginal effects, the nine identified loci together only explain
5.22% of the SUA level variation [11], suggesting there may be
more genetic loci to be detected.
One possible source of the unexplained variation in SUA levels
is gene-gene interaction (epistasis) [13,14]. Epistasis remains
largely unexplored in previous GWA studies of SUA levels due
to computational and statistical challenges, e.g. the lack of widely
accepted algorithms that are fast enough to effectively handle high
density SNPs and map different forms of epistasis while keeping
false positive rates under control [15]. With the advances in
computing technologies (e.g. GRID computing), full pair-wise
genome scans are beginning to be applied in GWA data analyses
[16,17]. Nonetheless, fundamental questions about the potential
values of GWA epistasis studies of normal GWA populations
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remain to be answered. Therefore, we performed a full pair-wise
genome association scan in the Italian MICROS study cohort [18]
to generate a profile of epistasis signals in SUA levels. The pair-
wise genome scan used a regression-based comprehensive search
algorithm that can detect epistasis signals with and without main
effects [15,19]. Epistasis signals detected in MICROS were tested
for replication in a CROATIAN population combining the VIS
[20] and KORCULA [21] study cohorts as well as the SOCCS
(Phase 1) cohort [22]. Furthermore, we examined the gene
ontology (GO) terms [23] enriched by the epistasis signals in both
discovery and replication populations for any new insights into the
genetic regulation of SUA levels.
Materials and Methods
Study cohorts and Ethics statement
The Italian MICROS cohort was recruited from the villages in
South Tyrol [18]. This study was approved by the ethical
committee of the Autonomous Province of Bolzano. The VIS [20]
and KORCULA [21] cohorts were recruited from the islands of
Vis and Korcula in Croatia respectively. This study was approved
by the Ethical Committee of the Medical School, University of
Zagreb and the Multi-Centre Research Ethics Committee for
Scotland. The SOCCS (Phase 1) cohort was recruited in Scotland
to study colorectal cancer [22]. This study was approved by the
MultiCentre Research Ethics committee for Scotland. All
participants gave written informed consent and were measured
for a number of traits including SUA level, weight and height from
which body mass index (BMI) values were calculated.
DNA samples were genotyped with Illumina Infinium Human-
Hap300v1/v2 or HumanCNV370v1 SNP bead microarrays and
analyzed using the BeadStudio software. Quality control of the
genotype data was performed for each cohort using the R/
GenABEL package (Version 1.4.3) [24] based on a common set of
criteria: individual call rate at 95%, SNP call rate at 98%, P value
for deviation from Hardy-Weinberg equilibrium at 1.0e-10, minor
allele frequency at 2%. The sample size and number of SNPs after
the quality control were listed in Table 1 for each cohort.
Statistical analysis
In each individual cohort the raw SUA levels were corrected for
age, sex and BMI and normalised using the rntransform function
that is implemented in the GenABEL package performing quantile
normalisation of residuals from a generalized linear model
analysis. The normalised SUA levels were then analysed using a
linear mixed model to correct for polygenic effects and relatedness
using the polygenic function in the GenABEL package and the
resultant environmental residuals (i.e. pgresidualY) were used as
the trait to test for association [25]. Polygenic heritability was
estimated at the mixed model step. The CROATIAN combined
population was created by merging the VIS and KORCULA
study cohorts and the normalised SUA levels were corrected for
study cohort, polygenic effects and relatedness as above and the
resultant residuals were used as the trait for association tests.
A single SNP based GWA scan was performed in each
population using a score test method (based on the additive
model) implemented in the mmscore function in the GenABEL
package. The consensus GWA threshold of 7.3 (2log10(5.0E-08))
was applied to identify GWA significant SNPs [26]. A full pair-
wise genome scan was followed using regression models.
Considering a pair of SNPs denoted as SNP1 and SNP2, the
following genetic models are used to detect epistasis where
genotypes of each SNP (i.e. homozygote of the minor allele,
homozygote of the major allele and heterozygote) were fitted as
fixed factors [19,27]:
Model 1 : y~mzSNP1zSNP2z
SNP1  SNP2ze
(two SNPs with interaction)
Model 2 : y~mzSNP1zSNP2ze two SNPs without interactionð Þ
Model 3 : y~mze NULL modelð Þ
where y is the trait of interest, m is the model constant, SNP1 (or
SNP2) is a fixed factor with three levels, SNP1*SNP2 is the
interaction term, e is the random error term. The F ratio test of
Model 1 against Model 3 is for the whole pair effect including
interaction (i.e. Fpair, 8 degrees of freedom). The F ratio test of
Model 1 against Model 2 is for the interaction between the two
SNPs (i.e. Fint, 4 degrees of freedom). SNP pairs with missing joint
genotype classes (i.e. considering three genotypes per SNP, at least
one of the nine joint genotype classes of a SNP pair had no
individuals) were not evaluated to reduced the risk of inflation of
the type I error rate. P values were calculated based on the F
distribution with relevant degrees of freedom and transformed in
the2log10 scale (i.e.2log10Ppair for the Fpair test,2log10Pint for the
Fint test). We applied the same 2log10 scaled thresholds for both
the Fpair and Fint tests to control the type I error rate [15].
Genome-wide significance thresholds (all in the 2log10 scale)
were derived based on Bonferroni correction for multiple tests, i.e.
the 5% nominal P value corrected by the number of pair-wise
tests. Considering 300,000 SNPs, a SNP-genome scan and a full
pair-wise genome scan perform 3.0E+05 and 4.5E+10 association
tests respectively, thus the genome-wide threshold is 11.95
(2log10(0.05/4.5E+10)) for the pair-wise genome scan. SNP-
genome scans have been used to test epistasis for genome-wide
significant signals specifically to increase the power of detection
Table 1. Summary information of each study cohort.*
MICROS VIS KORCULA CROATIAN SOCCS
N 1201 895 877 1772 1097
#SNP 293913 300265 307712 283971 305449
SUA_median 5.17 5.09 4.84 NA 4.41
SUA_mean 6 SD 5.3261.42 5.2461.59 4.9161.29 NA 4.6061.25
SUA and BMI correlation 0.38 0.35 0.38 NA 0.24
SUA polygenic heritability 0.325 0.288 0.228 0.287 NA
*: SUA level in mg/dL; CROATIAN combined VIS and KORCULA; NA: not available; the phenotypic correlation between SUA level and BMI was significant (P,2.2E-16)
across MICROS, VIS and KORCULA.
doi:10.1371/journal.pone.0023836.t001
GWA Epistasis in Serum Uric Acid
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[15,19,28,29] and thus are applied here to examine the
interactions between each GWA significant SNP and all other
SNPs genotyped. The actual GWA threshold for SNP-genome
scans is calculated as 2log10(0.05/3.0E+05/N) if there are N
GWA significant SNPs.
A full pair-wise genome scan was performed in the MICROS
population and SNP pairs with a certain interaction signal (i.e.
2log10Ppair.4.7 and 2log10Pint.3.2) were retained. The retained
results were evaluated using the predefined thresholds to identify
genome-wide significant epistatic signals. Each SNP in the
retained results was annotated to the nearest gene within a
window of 20 kilobases flanking the SNP based on the physical
distances to either the start or end of transcription of genes (the
distance is set to zero if the SNP is within a gene) without
considering linkage disequilibrium (LD). A full pair-wise genome
scan was also performed in the CROATIAN population as above
to prepare input for GO enrichment analyses (see below).
Replication, variance explained, and GO enrichment
analysis
Epistatic pairs detected in the MICROS population were tested
for replication in the CROATIAN population following the same
procedures as above. The nominal threshold of 0.05 (or 0.05/K, if
K epistatic pairs were tested) was used to claim significant
replication for an epistatic pair (i.e. both replicated SNPs were
exactly the same as the epistatic SNPs) because only one test was
performed. When an epistatic pair was not replicated (e.g. due to
missing genotype classes), we also tested the interactions between
each of the adjacent SNPs of the first epistatic SNP and that of the
second. In that case, the nominal threshold corrected by the actual
number of tests was used to claim significant replication.
The polygenic function was also used to calculate the proportion
of the phenotypic variance in SUA levels explained by epistatic
pairs in the MICROS population. Because the quantile normal-
ised SUA levels were based on the quantiles of the raw SUA levels,
we used standardized SUA levels for variance calculation (i.e. the
raw SUA levels were corrected for age, sex and BMI and then
standardized (mean of 0 and variance of 1)). The standardized
SUA levels were fitted into the full mixed model including
polygenic effects and the identified SNP pairs. The difference of
residual variance from a value of 1 is the proportion of phenotypic
variance explained by the SNP pairs included.
A GO enrichment analysis was conducted for each of the
MICROS and CROATIAN populations using the running mode
of ‘‘Two unranked lists of genes’’ in GOrilla [23] where the full list
of human genes was used as the background. We chose SNP pairs
with a moderately high interaction signal (i.e.2log10Ppair.6.5 and
2log10Pint.6.5) in each population and used the epistatic genes
annotated from them as the target for the GO enrichment analysis
to mine biological meanings from epistatic signals that were less
significant. The GO terms enriched (P,1.0E-03) by the epistatic
genes in each population were compared to identify replicated GO
terms and then epistatic genes shared by each pair of replicated
GO terms. The shared epistatic genes in the replicated GO terms
were investigated further for a) associated biological functions or
diseases and b) epistatic SNP pairs involved and their replication.
Results
The mean SUA level and phenotypic correlation between SUA
level and BMI were similar across the MICROS, VIS and
KORCULA cohorts (Table 1). The polygenic heritability estimates
varied from 0.228 (KORCULA) to 0.325 (MICROS), suggesting a
different genetic background in each individual cohort. Using the
normalised SUA residuals as the trait, a conventional GWA scan
identified seven genome-wide significant SNPs in MICROS:
rs737267, rs13129697, rs13131257, rs6449213, rs1014290,
rs10805346 and rs733175 that were all annotated to the SLC2A9
gene. The GWA scan for the CROATIAN population also
identified seven genome-wide significant SNPs which were exactly
the same as those in MICROS. Thus the genome-wide threshold of
7.62 (2log10(0.05/3.0E+05/7) was used for SNP-genome scans.
The inflation factor l (computed by regression in a quantile-
quantile (QQ) plot, Figure S1) was 1.007 in both GWA scans,
suggesting the family relatedness was well accounted for. In the
SOCCS cohort 1097 unrelated individuals were measured for SUA
and BMI where the mean SUA level (4.6061.25) was lower than
those in the three cohorts above (Table 1).
The full pair-wise genome scan in the MICROS population
tested 43 billion pair-wise SNP combinations where 11 billion
pairs (26.3%) had missing joint genotype classes and hence were
ignored in this study. We plotted the P values of all the Fpair and Fint
tests performed on chromosomes 3 and 4 (the total number of
pair-wise combinations is too large to plot at the genome level) to
illustrate why the two tests are needed (Figure 1). Using only the
Fpair test (e.g. 2log10Ppair.11.95 may pick up SNP pairs with very
weak interactions (e.g. 2log10Pint,3), whereas using only the Fint
test (e.g. 2log10Pint.7.62) could pick up those with weak whole
pair effects when both SNPs had small marginal effects (e.g.
2log10Ppair,6) (Figure 1a). The QQ plot for the Fpair tests
(Figure 1b) showed an earlier departure (near the value of 3) from
the expected line and that for the Fint tests (Figure 1c) showed a late
departure from the expected line. The QQ plots suggested that
many pairs of SNPs on chromosomes 3 and 4 had strong whole
pair effects attributing to the marginal effects in the SLC2A9 region
but only a few of them with interactions greater than expected
under the null hypothesis. To further check the distributions of the
test statistics, we randomly sampled 5000 SNPs from the
MICROS genome and tested and stored all their pair-wise
interactions with and without permutation. The two- sample
Kolmogorov-Smirnov tests [30] found no significant difference
(D=0.0044, P.0.05) between the real (without permutation)
2log10Pint distribution and the 2log10Pint distribution under the
null hypothesis.
We plotted the pair-wise tests for all the SNP pairs
(2log10Ppair.4.7 and 2log10Pint.3.2, 212933 in total) retained
from the full pair-wise genome scan (Figure 2). No SNP pairs
reached the pair-wise genome scan threshold (i.e. 2log10Pint.
11.95 along the x axis). However, we found a big cluster
of SNP pairs with strong whole pair effects (i.e. 2log10Ppair.11.95
along the y axis) but weak to high interactions (i.e. 3.2,
2log10Pint,8.5 along the x axis). This cluster of SNP pairs all
involved the SLC2A9 gene as one would expect. Two pairs:
rs12130085 (NFIA) – rs737267 (SLC2A9) and rs737267 (SLC2A9) –
rs9316212 (ESRRAP2) were significant based on the threshold of
7.62 for SNP-genome scans (Table 2). These two pairs showed
different interaction patterns (Figure S2) and jointly explained
8.0% (4.4% by rs727367 alone and 3.4% by interactions) of the
variance of the standardised SUA levels in MICROS.
Considering only those with a moderately high interaction
signal (2log10Ppair.6.5 and 2log10Pint.6.5), in total 1326 SNP
pairs involved 2063 unique SNPs of which 1148 (55.6%) were
annotated to 910 unique genes, i.e. 1.5 pairs per gene. In contrast,
17 out of the 1326 SNP pairs involved the SLC2A9 gene including
4 GWA significant SNPs rs733175, rs737267, rs13131257 and
rs13129697 (Tables 2 and S1). Epistatic pairs listed in Table 2
were tested for statistical replication in the CROATIAN
population. The two genome-wide significant epistatic pairs
GWA Epistasis in Serum Uric Acid
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missed the SNP level replication: the 2log10Pint values of the best
replicated pairs of rs737267 – rs1779851 (adjacent to rs12130085)
and rs737267 – rs17064136 (adjacent to rs9316212) were 1.35 and
1.32 respectively. Combining the MICROS and CROATIAN
data did not make the two significant pairs stronger (2log10Pint
was 2.32 and 2.19 respectively) which is in line with the replication
results. The two less significant SLC2A9 epistatic pairs also missed
the SNP level replication in the CROATIAN population (Table 2).
The four epistatic pairs in Table 2 also failed to achieve exact
replication in the SOCCS cohort.
Epistatic genes annotated from the less significant SNP pairs (i.e.
2log10Ppair.6.5 and2log10Pint.6.5) in MICROS (910 genes from
1326 pairs) and CROATIAN (984 genes from 1260 pairs) were
tested for GO enrichment. The GO terms enriched by epistatic
genes in MICROS showed a complicated relationship among
biological functions (e.g. calmodulin binding, transporter activity)
and highlighted the importance of glutamate receptor activity
(Figure 3). Clearly, more than 50% of the GO terms enriched
(P,1.0E-05) in MICROS were also enriched in CROATIAN
(Table 3, Figures S3 and S4) which suggested GO terms regarding
nervous system, synapse, glutamate receptors and plasma mem-
brane were important in both populations. Comparing the epistatic
genes enriched the 13 replicated GO terms (Table 3), we found 82
genes shared by both populations including SLC2A9 and a number
of glutamate receptor genes (GRID1, GRIK1, GRIK2, GRM7 and
GRIN2A) (Table S2). Surprisingly, 53 out of the 82 shared epistatic
genes are previously published GWA loci [31] associated with
phenotypes such as multiple sclerosis, Alzheimer’s disease, bipolar
disorder and schizophrenia, cognition and diabetes. Among SNP
pairs where both SNPs were gene annotated and with at least one of
the 82 shared epistatic genes from the retained results, we found 49
epistatic gene pairs (correspondingly to 120 SNP pairs) in MICROS
were replicated in CROATIAN including SLC2A9 – LRRC16A
(interaction between two SUA candidate genes) (Table S3). Two
gene pairs were replicated exactly at the SNP level: rs737267
(SLC2A9) – rs4085921 (GPC6) and rs737267 (SLC2A9) – rs2302558
Figure 1. Plots of the P values of the pair-wise tests performed on chromosomes 3 and 4. SNP combinations with missing joint genotype
classes were excluded. Left: scatter plot of the 2log10Ppair against 2log10Pint values of each SNP pair. Upper-right: QQ plot of the whole pair tests.
Lower-right: QQ plot of the interaction tests.
doi:10.1371/journal.pone.0023836.g001
Figure 2. Profile of all retained epistatic pairs in the MICROS
population. Each epistatic pair in the figure with 2log10Ppair.4.7 and
2log10Pint.3.2.
doi:10.1371/journal.pone.0023836.g002
GWA Epistasis in Serum Uric Acid
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(CLEC16A). All the 49 epistatic gene pairs involved SLC2A9 and of
these 5 involved interactions with other shared epistatic genes:
ERC2, GPC6, CTNND2, CNTNAP2 and PTPRD. However, most of
the 49 replicated gene pairs had a relatively weak interaction signal
(2log10Pint,5).
Discussion
Using a full pair-wise genome-wide association scan we
generated a profile of epistasis in SUA levels in the Italian
MICROS population. No epistatic SNP pairs reached the
Bonferroni adjusted threshold for the pair-wise genome scan,
which was not a surprise because of the relatively small population
size. Nonetheless, we found that the SLC2A9 gene may be an
important epistatic locus interacting with multiple loci across the
genome more frequently than expected by chance (Tables 2 and
S1). Two SLC2A9 epistatic pairs (NFIA – SLC2A9 and SLC2A9 –
ESRRAP2) were significant in SNP-genome scans and jointly
explained 8.0% of the phenotypic variance in SUA levels where
3.4% was explained by their interaction components. However,
caution should be taken in light of the billions of tests performed,
the potential overestimation of the variance explained and the
limited replication of the two pairs. The NFIA (nuclear factor I/A)
gene is known as a cellular transcription DNA replication factor
and its haploinsufficiency is associated with a central nervous
system malformation syndrome and ureteral and renal defects
[32]. Recent GWA studies showed NFIA was responsible for celiac
disease [33] and ventricular depolarization and conduction [34].
The ESRRAP2 (estrogen-related receptor alpha pseudogene 2) is
not yet known to have any related functions.
The SLC2A9 gene is known to interact with sex, age and dietary
patterns [35,36,37] and GWA studies have identified several
common variants mapping to various introns and exons of the
locus [11,38,39,40]. The protein GLUT9 encoded by SLC2A9 is a
class II glucose/fructose transporter as well as high-capacity/low-
affinity urate transporter with two isoforms expressed in
basolateral and apical membranes of proximal renal tubular cells
respectively [41]. The complexity in the SLC2A9 polymorphism
was demonstrated further in two recent studies linking SUA levels
with human cognitive aging [42] and Parkinson’s disease [7]. Here
we showed that several GWA significant SNPs of SLC2A9 were
involved in epistatic interactions, which adds another dimension of
studying the SLC2A9 polymorphism and provides new clues of the
genetic mechanism underlying SUA levels.
The impact of SUA levels on human cognitive dysfunction has
been investigated in recent years [7,42,43,44]. It is still unclear
though whether high SUA levels causes disease associated aging or
vice versa. Considering most SUA associated genes identified from
GWA studies encode transporters, it is natural to speculate these
transporter genes interact with others that have moderate or low
marginal effects (thus not yet discovered in GWA studies) but with
certain regulatory roles. Our epistasis results and GO enrichment
analyses supported the speculation and showed that numerous
SLC2A9 interacting genes had clear neuronal influence (e.g.
synapse, glutamate receptors) and/or membrane functions
(Tables 2, S2, S3). It is noteworthy that the GO enrichment
results were almost identical after removing SLC2A9 and genes
that interacted with it (8 out of 910 unique genes in MICROS).
The epistatic genes encoding glutamate receptors (common in
both populations, Table S2) are particularly interesting because
glutamate receptors are implicated in the pathologies of a number
of neurodegenerative diseases due to their central role in
excitotoxicity and their prevalence throughout the central nervous
system [45,46]. A rat study showed that uric acid could protect the
neurons from glutamate-induced toxicity [47]. Furthermore, a
number of shared epistatic genes in the two populations (Table S2)
suggested links between SUA levels and various diseases such as
autism (CNTNAP2, POU6F2, MYO1D), schizophrenia and bipolar
disorder (ERC2, ROBO1, ROBO2, CNTNAP2, GRM7, SYNE1,
CNTN5, ANKS1B), Alzheimer’s disease (EPHA4, CNTN4, ADCY8,
PCSK5, CUBN, SORCS1, RORA, GRIN2A), Parkinson’s disease
(DLG2), sclerosis (RGS7, CNTN4, IGF2R, SH3GL2, GPC5, GPC6,
GRIN2A, MYH9), and diabetes (CD69, PTPRD, SORCS1, PREX1).
Statistically detecting and replicating an epistatic pair of SNPs is
far more challenging than for a single SNP signal for a number of
reasons. Whereas a single SNP association is dependent on strong
LD between the marker SNP and causative variant, detection of
epistasis requires strong LD for both loci. Small allele frequency
changes (e.g. 10%) between detection and replication populations
can lead to a dramatic loss of power in replication. Such small
allele frequency changes are not uncommon across the small and/
or isolated populations. The issue of missing joint genotype class in
replication populations (an extreme case of allele frequency
change) increases the difficulty of replication, especially when the
epistatic pair for test has a rare genotype class (e.g. less than 4
individuals in Table 2). These challenges support the case for
exploring epistatic effects and evidence for their replication at the
gene and/or pathway levels [48].
The lack of statistical replication at the SNP level may be not
too surprising considering that the epistatic signals detected in one
isolated sample were to replicate in another isolated sample
(CROATIAN) or a less isolated but smaller sample (i.e. SOCCS).
Even when all the retained SNP pairs were considered regardless,
we just found two SNP pairs (out of 212933) were replicated at the
Table 2. SLC2A9 involved epistatic pairs and replication.1
SNP1 chr1 gene1 SNP2 chr2 gene2 Ppair Pint MGC
CROATIAN
replication3
SOCCS
replication3
rs12130085 1 NFIA rs737267 4 SLC2A9 4.1e-17 (16.38) 6.6e-09 (8.20)2 2 0.045 0.178
rs737267 4 SLC2A9 rs9316212 13 ESRRAP2 6.2e-17 (16.21) 1.1e-08 (7.97)2 2 0.048 0.238
rs733175 4 SLC2A9 rs1818116 5 (-) 3.8e-12 (11.43) 5.5e-08 (7.27) 7 0.130 0.227
rs733175 4 SLC2A9 rs137180 22 SEZ6L 8.0e-11 (10.09) 2.6e-07 (6.58) 4 0.035 0.155
1: SNP1 (SNP2) – the first (second) SNP name; chr1 (chr2) – the chromosome where SNP1 (SNP2) locates; gene1 (gene2) – symbol of the gene annotated by SNP1 (SNP2);
Ppair – P value of the whole pair test (2log10 P value in brackets); Pint – P value of the interaction test (2log10 P value in brackets); MGC – count of number of individuals
in the minor joint genotype class; (-): no gene annotation.
2: genome-wide significant.
3: Best replication including adjacent SNPs: the SLC2A9 SNP is fixed and the other SNP is to replicate as itself or the first or second neighbour.
doi:10.1371/journal.pone.0023836.t002
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Figure 3. Gene function ontology enrichment by epistatic signals in the MICROS population.
doi:10.1371/journal.pone.0023836.g003
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SNP level. When testing for replication at the GO level, we found
13 GO enriched terms (.50%) were replicated. Clearly
replication improved dramatically as the level changes from SNP
to GO annotation. A high level replication (i.e. gene or GO/
pathway) does not guarantee a SNP level replication but is
valuable to understand the biology of interest. Therefore, we
recommend testing for replication of epistasis signals at all three
levels. For example, rs737267 (SLC2A9) – rs4085921 (GPC6) was
replicated at all three levels, rs737267 (SLC2A9) – rs2302558
(CLEC16A) at the SNP and gene levels but not the GO level as
CLEC16A is not associated with an enriched GO term. Both GPC6
(glypican 6) and CLEC16A (C-type lectin domain family 16,
member A) are associated with multiple sclerosis [49,50,51,52].
In addition to epistasis signal replication, this study also raises a
number of issues in GWA epistasis studies. First, it is difficult to
detect and replicate genome-wide epistasis signals in small samples
because of low power [53] and the problem of missing joint
genotype classes (i.e. 26.3% of the total SNP pairs skipped in
MICROS). It is suboptimal to ignore SNP pairs with missing
genotype classes as some might be true epistatic signals. Methods
such as the allelic model used in PLINK [17] and Pseudohaplo-
type [54] may be helpful to this situation but require further
investigation. A large sample size and use of relatively common
SNPs (e.g. minor allele frequency .5%) are a partial solution.
Second, proper genome-wide thresholds remain to be defined.
Bonferroni adjusted thresholds may be appropriate when the total
number of tests is close to the effective number of independent
tests [55] but may become over stringent when more SNPs are
genotyped in GWA studies. Permutation can be a good option but
is not yet feasible for GWA epistasis studies due to the excessive
computing demand. A set of consensus thresholds [26] will be very
useful to guide future GWA epistasis studies. Third, trait normality
is critical to the detection of epistasis so as to avoid inflated test
statistics simply because more parameters are fitted in an epistatic
model than an additive model. Increasing the sample size is a good
way to recover the power reduced by the use of quantile
normalisation. When it is not possible to do so, a good alternative
is to use GO enrichment and pathway analyses [56] to rescue
some true signals that are not genome-wide significant but jointly
important biologically. It is arguable what threshold should be
used to select a proper set of less significant epistatic pairs that
includes most true signals and excludes noise as much as possible.
A different threshold (other than2log10Pint of 6.5 used here) could
be chosen as long as the big cluster of SLC2A9 pairs was mostly
excluded (Figure 2) and sufficient epistatic genes were available for
the GO enrichment analysis. If we considered a threshold of 7.62,
there would be only 143 epistatic genes (from 111 SNP pairs) in
MICROS and 97 genes (from 96 SNP pairs) in CROATIAN
available for the enrichment analyses. The SNP-gene annotation
method could affect the GO analysis as well. Here we took a
commonly used method based on map distances and allowing only
one gene per SNP. This method is generally effective but has a
problem when genes overlap or the distances to two genes are
equal. In that case, either gene could be quoted depending on
which appears first in the annotation results. Such cases were rare
so our GO enrichment results were little affected. Nonetheless,
new methods are needed to make even more effective use of
epistasis signals than our demonstration where epistatic genes were
Table 3. Gene ontology terms enriched by epistatic genes in the MICROS population and their replication in the CROATIAN
population.*
GO Term Description MICROS CROATIAN
GO:0048731a system development 2.88E-10 1.50E-08
GO:0007166a cell surface receptor linked signaling pathway 6.26E-09 (-)
GO:0007268a synaptic transmission 1.85E-08 1.68E-05
GO:0007169a transmembrane receptor protein tyrosine kinase signaling pathway 3.27E-07 (-)
GO:0030224a monocyte differentiation 1.09E-06 (-)
GO:0007611a learning or memory 2.40E-06 (-)
GO:0007399a nervous system development 4.53E-06 4.39E-06
GO:0023052a signalling 6.22E-06 5.78E-04
GO:0031644a regulation of neurological system process 6.32E-06 5.63E-04
GO:0050890a cognition 8.41E-06 (-)
GO:0007267a cell-cell signalling 9.46E-06 (-)
GO:0007165a signal transduction 9.53E-06 6.35E-07
GO:0008066b glutamate receptor activity 3.39E-06 5.35E-05
GO:0004970b ionotropic glutamate receptor activity 7.82E-06 (-)
GO:0005516b calmodulin binding 9.68E-06 9.05E-05
GO:0044459c plasma membrane part 1.49E-08 1.38E-07
GO:0030054c cell junction 1.72E-08 2.25E-07
GO:0044456c synapse part 2.11E-07 4.95E-08
GO:0045202c synapse 2.96E-06 3.07E-08
GO:0005886c plasma membrane 7.09E-06 5.28E-07
*: displayed only GO terms with P,1.0E-05; 910 and 984 epistatic genes used in MICROS and CROATIAN respectively; (-): no enrichment at the P,1.0E-03 level.
a: gene process ontology;
b: gene function ontology;
c: gene component ontology.
doi:10.1371/journal.pone.0023836.t003
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treated independently and more than 40% epistatic SNPs were not
gene annotated and hence not considered.
In summary, this study characterized epistasis signals in SUA
levels in the MICROS population and shows that SLC2A9 may be
an important epistatic locus interacting with multiple loci across
the genome, including those with neuronal influence and/or
associating with neurological disorders. Two SLC2A9 epistatic
pairs were genome-wide significant and explained additional
phenotypic variance in SUA levels via interactions. We conclude
that GWA epistasis study is useful and can provide new insights
into the trait of interest in conjunction with GO/pathway
enrichment analysis utilising less significant epistatic signals.
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